P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)
Bruno Paiva,
Anastasiia Zherniakova,
Jorge Nuñez,
Paula Rodríguez-Otero,
Qian Shi,
Nikhil Munshi,
Brian Durie,
Jesús San Miguel
Affiliations
Bruno Paiva
1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain
Anastasiia Zherniakova
1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain
Jorge Nuñez
1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain
Paula Rodríguez-Otero
1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain
Qian Shi
2 Mayo Clinic, Rochester, United States
Nikhil Munshi
3 Dana-Farber Cancer Institute, Boston, United States
Brian Durie
4 Cedars-Sinai Medical Center, Los Angeles, United States
Jesús San Miguel
1 Clinica Universidad de Navarra, Hematology, Pamplona, Spain
